US Stock MarketDetailed Quotes
LPCN Lipocine
- 5.0100
- +0.0900+1.83%
Close May 7 16:00 ET
- 5.0600
- +0.0500+1.00%
Post 19:51 ET
26.79MMarket Cap-1595P/E (TTM)
5.2000High5.0100Low21.82KVolume5.0300Open4.9200Pre Close111.40KTurnover0.42%Turnover RatioLossP/E (Static)5.35MShares7.150052wk High1.32P/B26.00MFloat Cap2.310152wk Low--Dividend TTM5.19MShs Float1461.9999Historical High--Div YieldTTM3.86%Amplitude2.3100Historical Low5.1040Avg Price1Lot Size
About Lipocine Company
Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers TLANDO, an oral testosterone replacement therapy. The company was founded on October 13, 2011 and is headquartered in Salt Lake City, UT.
Company Profile
SymbolLPCN
Company NameLipocine
Listing DateMar 21, 2014
Founded2011
CEOMr. Mahesh V. Patel, PhD
MarketNASDAQ
Employees17
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address675 Arapeen Drive,Suite 202
CitySalt Lake City
ProvinceUtah
CountryUnited States of America
Zip Code84108
Phone1-801-994-7383
Websitehttp://www.lipocine.com
Company Executives
- Name
- Position
- Salary
- Mahesh V. Patel, PhD
- Director, President, Chief Executive Officer and Chief Financial Officer
- 883.85K
- Krista Fogarty
- Principal Accounting Officer and Corporate Controller
- 297.78K
- Nachiappan Chidambaram, PhD
- Senior Vice President, Research and Development
- 352.20K
- Dr. Spyros Papapetropoulos, M.D.
- Lead Independent Director and Chairman of the Board
- 61.26K
- John W. Higuchi, M.B.A.
- Director
- 50.69K
- Jeffrey A Fink
- Independent Director
- 73.44K
- Dr. Jill M. Jene
- Independent Director
- 55.01K
- Dr. Richard Dana Ono
- Independent Director
- 66.94K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg